Middle East Respiratory Syndrome (MERS) Market

Market Overview:

The Middle East respiratory syndrome (MERS) market reached a value of USD 11.2 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 34.0 Billion by 2035, exhibiting a growth rate (CAGR) of 10.69% during 2025-2035.

The Middle East respiratory syndrome (MERS) market has been comprehensively analyzed in IMARC's new report titled "Middle East Respiratory Syndrome (MERS) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Middle East respiratory syndrome (MERS) is a viral sickness that causes severe lung infections. This condition is caused by the Middle East respiratory syndrome coronavirus (MERS-CoV), a zoonotic virus that can infect humans, bats, and camels. It is commonly transmitted by close contact with an infected person. An individual with MERS may experience no symptoms, moderate cold-like signs, or a severe life-threatening infection. Typically, patients might suffer from respiratory problems, like cough with or without blood, pain in the chest, fever, headache, congestion, sneezing, sore throat, shortness of breath, etc. Some people have reported diarrhea, muscle and stomach pain, nausea, loss of appetite, and vomiting. MERS symptoms usually appear within two to 14 days after exposure to the virus. The diagnostic evaluation of this condition is based on a combination of clinical observation, travel history review, and physical examination. The healthcare professional might also recommend blood tests or chest X-rays to assess the severity of the illness and rule out other diseases.

The escalating prevalence of viral diseases, in which the virus spreads from human-to-human transmission through respiratory droplets, direct contact, or contaminated surfaces, is primarily driving the Middle East respiratory syndrome (MERS) market. In addition to this, the inflating utilization of antiviral medications, like ribavirin, to inhibit viral RNA synthesis and block viral entry into human cells, is also creating a positive outlook for the market. Moreover, the widespread adoption of oxygen therapy on account of its numerous advantages, such as enhanced tissue healing, reduced fatigue and weakness, and improved survival rates, is further bolstering the market growth. Apart from this, the rising usage of non-invasive positive pressure ventilation, since it involves the delivery of oxygen into the lungs via positive pressure without the need for endotracheal intubation, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of monoclonal antibodies (mAbs) that are designed to target and neutralize the MERS-CoV by blocking its ability to infect human cells is expected to drive the Middle East respiratory syndrome (MERS) market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the Middle East respiratory syndrome (MERS) market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Middle East respiratory syndrome (MERS) and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Middle East respiratory syndrome (MERS) market in any manner.

Drugs:

Astodrimer, developed by Starpharma, is a dendrimer-based antiviral agent that exhibits activity against various coronaviruses, including the Middle East respiratory syndrome coronavirus (MERS-CoV). Its mechanism of action involves binding to the positively charged regions of the MERS-CoV spike protein, thereby preventing the virus from attaching to host cell receptors, such as dipeptidyl peptidase-4 (DPP4). This inhibition blocks viral entry into host cells, effectively reducing infection rates.

RVX 25 is a vaccine candidate developed by RocketVax for Middle East respiratory syndrome (MERS). It utilizes RocketVax's proprietary Viruflex platform, which enables the design of live-attenuated vaccines through synthetic genomics. The mechanism involves genetically modifying the MERS-CoV virus to weaken its pathogenicity while retaining its antigenic properties. This attenuation allows the virus to stimulate the immune system without causing disease, promoting the development of a robust and long-lasting immune response. By mimicking a natural infection, RVX 25 aims to elicit both humoral and cellular immunity, providing comprehensive protection against MERS.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Middle East respiratory syndrome (MERS) market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Middle East respiratory syndrome (MERS) market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Middle East respiratory syndrome (MERS) marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Middle East respiratory syndrome (MERS) market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the Middle East respiratory syndrome (MERS) market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the Middle East respiratory syndrome (MERS) market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of Middle East respiratory syndrome (MERS) across the seven major markets?
• What is the number of prevalent cases (2019-2035) of Middle East respiratory syndrome (MERS) by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of Middle East respiratory syndrome (MERS) by gender across the seven major markets?
• How many patients are diagnosed (2019-2035) with Middle East respiratory syndrome (MERS) across the seven major markets?
• What is the size of the Middle East respiratory syndrome (MERS) patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of Middle East respiratory syndrome (MERS)?
• What will be the growth rate of patients across the seven major markets?

Middle East Respiratory Syndrome (MERS): Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Middle East respiratory syndrome (MERS) drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Middle East respiratory syndrome (MERS) market?
• What are the key regulatory events related to the Middle East respiratory syndrome (MERS) market?
• What is the structure of clinical trial landscape by status related to the Middle East respiratory syndrome (MERS) market?
• What is the structure of clinical trial landscape by phase related to the Middle East respiratory syndrome (MERS) market?
• What is the structure of clinical trial landscape by route of administration related to the Middle East respiratory syndrome (MERS) market?